These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20885402)

  • 21. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 22. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 23. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
    Detournay B
    Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
    [No Abstract]   [Full Text] [Related]  

  • 24. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
    Rudick RA
    Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
    Phillips CJ
    CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation.
    Rajagopalan K; Brook RA; Beren IA; Kleinman NL
    Curr Med Res Opin; 2011 Jan; 27(1):179-88. PubMed ID: 21138336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple sclerosis treatment 2001.
    Rolak LA
    Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-beta1b for the treatment of multiple sclerosis.
    Lam S; Wang S; Gottesman M
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 35. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 39. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.